NCT02312557View on ClinicalTrials.gov

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 18, 2014

Primary Completion Date

August 22, 2024

Study Completion Date

June 30, 2025

Conditions
Castration-Resistant Prostate CarcinomaHormone-Resistant Prostate CancerPSA ProgressionRecurrent Prostate CarcinomaStage IV Prostate Adenocarcinoma Cancer AJCC v8
Interventions
DRUG

Enzalutamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

Collins Medical Trust
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Collins Medical Trust

OTHER

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER